Management Change27 Oct 2026, 10:15 am
Dr. Claudio Albrecht's Designation Changes at Onesource Specialty Pharma
AI Summary
Onesource Specialty Pharma Ltd announced a change in the designation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director. This change was approved by the Board of Directors on October 27, 2026, based on the recommendation of the Nomination and Remuneration Committee. The change is subject to shareholder approval. Dr. Albrecht, who is not related to any other director, has extensive experience in the generics and pharmaceutical investment sectors, having previously served as CEO of Ratiopharm Group, Actavis Group, and STADA AG. He is not debarred from holding a directorship.
Key Highlights
- Dr. Claudio Albrecht's designation changed from Independent to Non-Executive Non-Independent Director.
- The change is effective October 27, 2026, pending shareholder approval.
- Dr. Albrecht has significant international experience in the pharmaceutical industry.
- He is not related to any other directors of the company.
- He is not barred from holding a director position by any authority.
Price Impact
More from ONESOURCE